Tag: DIAL
Vaccination Cuts Risk of Severe COVID-19 in Patients on Dialysis
Reduction in risk of admission and deaths with prior two-dose vaccination versus no vaccination
Rapid Recovery Seen With More Frequent Dialysis in SNFs
Rapid recovery associated with reduced mortality and fewer hospitalizations
Cardiovascular Mortality Down Among Dialysis Patients
Greater declines seen for myocardial infarction, stroke, and pulmonary embolism among dialysis patients than general population
Vaccine Rollout Linked to Drop in Severe COVID-19 in Dialysis Patients
And, patients on maintenance dialysis who received COVID-19 vaccination had decreasing antibody titers over time
Humoral Response in Hemodialysis Patients Stronger With mRNA-1273
Antibody responses at six to seven and 12 weeks after the second dose stronger with mRNA-1273 versus BNT162b2
High-Dose IV Iron Reduces MI in Patients on Hemodialysis
High-dose versus low-dose intravenous iron reduces myocardial infarctions in patients receiving maintenance hemodialysis
Antibody Response to SARS-CoV-2 Wanes Among Dialysis Patients
Prebreakthrough index RBD values of <10 and 10 to <23 associated with increased odds of breakthrough infection versus value of ≥23
ASN: Ellipsys Percutaneous Fistula Durable for Hemodialysis Access
High rate of fistula use, low rates of secondary procedures and complications seen at five years
For Dialysis Recipients, Antibody Response Lowest With Ad26.COV2.S
Patients receiving attenuated adenovirus vaccine more likely to have no seroconversion, no detectable or diminished IgG response
Hemodialysis Patients Have Antibody Response to COVID-19 Vaccine
But few kidney transplant recipients develop anti-spike SARS-CoV-2 antibodies after second mRNA vaccine dose